Efficacy and Safety of the Ultrasound Stimulation Device NEFRONIX in Patients With Chronic Kidney Disease

A Prospective, Multicenter, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Glomerular Filtration Rate (GFR-EPI) Using NEFRONIX in Patients With Chronic Kidney Disease (CKD)

This study is a prospective, multicenter, single-arm, open-label, non-randomized exploratory clinical trial designed to evaluate the safety and potential efficacy of an ultrasound stimulation device (NEFRONIX G-01) in patients with chronic kidney disease (CKD). Baseline functional assessments will be performed prior to intervention. Participants will receive ultrasound stimulation applied to the kidneys three times per week for four weeks according to the study protocol. Clinical evaluations will be conducted at baseline, at the end of treatment, and 12 weeks after completion of treatment. Renal function will be assessed using changes in estimated glomerular filtration rate based on serum creatinine (CKD-EPI eGFR Cr) and cystatin C (CKD-EPI eGFR CysC). Additional assessments will include imaging studies (Tc-99m DTPA renal scintigraphy and renal ultrasonography), urinalysis for proteinuria, inflammatory markers (high-sensitivity C-reactive protein), and renal injury biomarkers (neutrophil gelatinase-associated lipocalin).

Study Overview

• Status: Not yet recruiting
• Conditions: Chronic Kidney Disease
• Intervention / Treatment: Device: Ultrasound Stimulation (NEFRONIX G-01)

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: SungKyung Lee; Phone Number: 82+10-9877-8173; Email: sklee@deepsonbio.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants who have received sufficient explanation of the study and have voluntarily provided written informed consent.
• Male and female adults aged 18 to 65 years at the time of consent.
• Participants with chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m².
• Participants who agree to use and maintain appropriate contraception throughout the study period.

Exclusion Criteria:

• Participants currently enrolled in another clinical study with an ongoing follow-up period.
• Participants with heart failure.
• Participants who have undergone reperfusion therapy for cardiovascular disease within the past year.
• Participants with platelet or coagulation disorders, including those receiving antithrombotic therapy.
• Participants with acute or chronic urinary tract infection.
• Participants with polycystic kidneys.
• Participants with anatomical kidney abnormalities (e.g., solitary kidney, horseshoe kidney, polycystic kidney disease) as determined by the investigator.
• Participants with urinary tract obstruction.
• Participants who have received a kidney transplant.
• Participants with kidney or urinary tract stones.
• Participants who have experienced acute kidney injury or changes in CKD stage within the past 3 months.
• Participants with serum albumin <3.0 g/dL and either 24-hour proteinuria ≥3.0 g/day or random urine protein/creatinine ratio ≥3.0 mg/mg.
• Participants with uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg despite treatment with two or more antihypertensive medications).
• Participants with liver dysfunction.
• Participants receiving immunosuppressive therapy.
• Participants with body mass index (BMI) >35 kg/m² or body weight <40 kg.
• Participants with a history of severe illness, such as cancer or tuberculosis.
• Participants with contact dermatitis or other significant skin sensitivities.
• Participants with fever ≥40°C (104°F) measured via tympanic temperature.
• Participants deemed unsuitable for participation in the study by the investigator for any other reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NEFRONIX Treatment; Participants in this arm will receive ultrasound stimulation using the NEFRONIX G-01 device applied to the kidneys three times per week for four weeks, in accordance with the study protocol. Standard clinical care for chronic kidney disease will be maintained throughout the study period.	Device: Ultrasound Stimulation (NEFRONIX G-01); Ultrasound stimulation will be delivered to the renal area using the NEFRONIX G-01 device. The intervention will be administered three times per week for four weeks in accordance with the study protocol. Standard clinical management for chronic kidney disease will be continued during the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Glomerular Filtration Rate Estimated by Serum Creatinine (eGFR-EPI Cr)	The primary outcome is the change in glomerular filtration rate estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on serum creatinine (eGFR-EPI Cr) from baseline to after 4 weeks of application of the investigational medical device.	Baseline to after 4 weeks of application of the investigational medical device

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in Glomerular Filtration Rate Estimated by Serum Creatinine (eGFR-EPI Cr)	Baseline to 12 weeks after application of the investigational medical device
Change in Glomerular Filtration Rate Estimated by Cystatin C (eGFR-EPI CysC)	Baseline to after 4 weeks of application of the investigational medical device
Change in Glomerular Filtration Rate Estimated by Cystatin C (eGFR-EPI CysC)	Baseline to 12 weeks after application of the investigational medical device
Change in Renal Function Assessed by Tc-99m DTPA Renal Scintigraphy	Baseline to after 4 weeks of application of the investigational medical device
Change in Renal Function Assessed by Tc-99m DTPA Renal Scintigraphy	Baseline to 12 weeks after application of the investigational medical device
Change From Baseline in Urinary Protein Excretion	Baseline to after 4 weeks of application of the investigational medical device
Change From Baseline in Urinary Protein Excretion	Baseline to 12 weeks after application of the investigational medical device
Change From Baseline in Serum High-Sensitivity C-Reactive Protein (hsCRP) Concentration	Baseline to after 4 weeks of application of the investigational medical device
Change From Baseline in Serum High-Sensitivity C-Reactive Protein (hsCRP) Concentration	Baseline to 12 weeks after application of the investigational medical device
Change From Baseline in Renal Resistive Index Assessed by Doppler Ultrasonography	Baseline to after 4 weeks of application of the investigational medical device
Change From Baseline in Renal Resistive Index Assessed by Doppler Ultrasonography	Baseline to 12 weeks after application of the investigational medical device
Change From Baseline in Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration	Baseline to after 4 weeks of application of the investigational medical device
Change From Baseline in Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration	Baseline to 12 weeks after application of the investigational medical device

Collaborators and Investigators

• Sponsor: Anasonic

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: January 5, 2026
• First Submitted That Met QC Criteria: January 5, 2026
• First Posted (Estimated): January 14, 2026

Study Record Updates

• Last Update Posted (Actual): January 15, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Renal Insufficiency; Pathological Conditions, Signs and Symptoms; Renal Insufficiency, Chronic
• Other Study ID Numbers: Cenovia; 1866 (Other Identifier: Ministry of Food and Drug Safety (MFDS))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No